Tag Archives: Utah

Are Pharmacies the New Dispensary Model? Utah Thinks So

Georgia has captured national attention by allowing medical cannabis to be sold through independent pharmacies. Utah has spent the past six years developing another version of the pharmacy model, one designed specifically for cannabis.

Utah’s medical cannabis pharmacies do not dispense conventional prescription drugs. They sell cannabis products exclusively, but each location must have a licensed pharmacist available to consult with patients about dosage, delivery methods, medications, and possible drug interactions.

With medical marijuana’s move to Schedule III and adult-use reform hopefully not far behind, the outlines of a national medical model are beginning to take shape. Cannabis businesses preparing to participate in a federally regulated medical market may need more clinical oversight, stronger manufacturing standards and tighter inventory controls than most dispensaries currently provide.

Narith Panh, chief growth officer at Dragonfly Wellness, believes Utah offers an early look at how such a system could operate.

“Utah is the blueprint for what a future Schedule III medical cannabis future looks like,” he said.

 

A Pharmacy Instead of a Dispensary

Utah opened its medical cannabis market in 2020 with physician involvement, patient cards and a limited number of licensed pharmacies. State lawmakers have shown little interest in legalizing adult-use cannabis, leaving the medical program as the only regulated path to marijuana in the state.

Dragonfly operates two of Utah’s 15 medical cannabis pharmacies. Patients are required to consult with a pharmacist when they enter the program, regardless of their previous cannabis experience.

The pharmacist reviews why the patient is seeking cannabis, what medications the patient takes and whether there are potential contraindications. The consultation can also cover dosage, product format and how the patient has responded to cannabis in the past.

Panh points to the difference between walking into a retail dispensary and asking a budtender what to buy.

“We have people who have real conditions that are seeking cannabis as an alternative treatment,” he said.

Many are using cannabis for the first time. Some want symptom relief without feeling high. Others are older patients or people managing serious conditions while taking several prescription medications.

Panh said cannabis should not be presented as completely risk-free merely because it is considered safer than many other controlled substances. Consumers should be aware of possible drug interactions and how delivery method and dosage can affect the experience.

“If you really want to consider cannabis as medicine, it’s important to understand your medical history,” he said.

A first-time patient would not be directed toward a concentrate or another high-potency product without understanding the possible effects. The pharmacist can recommend a lower dose or a delivery method more appropriate for the patient’s needs.

 

Medical and Adult Use May Follow Different Paths

While medical marijuana has moved to Schedule III and adult-use cannabis remains federally illegal, Panh believes the two markets could eventually operate under different federal systems. Medical cannabis would move through physicians, pharmacists, and licensed healthcare facilities. Adult-use cannabis could eventually be regulated more like alcohol.

Businesses would then have to decide which market they intend to serve.

Panh does not expect adult-use dispensaries to disappear. He sees a continued place for products sold to consumers 21 and older without physician involvement. Participation in a medical market would carry different responsibilities and costs.

A company could continue selling to adult consumers, enter a medical system or create separate operations for each. Businesses choosing the medical path may need pharmacists, DEA registration, pharmaceutical quality systems, and more extensive documentation than state cannabis laws currently require.

The elimination of the Section 280E tax burden has been one of the most anticipated financial effects of Schedule III. Panh said the industry should also account for the cost of meeting medical standards. Hiring licensed pharmacists adds a considerable payroll expense. Pharmaceutical quality management systems can be costly to implement and operate, while facilities may need additional security, inventory controls, manufacturing procedures, and employees trained to maintain federal records.

“If you want to talk about this big 280E relief that you’re going to get, you’re giving all that right back to all of these extra costs,” Panh said.

Small independent dispensaries could have the hardest time absorbing those expenses.

 

Manufacturing Standards Will Carry More Weight

Dragonfly manufactures cannabis products under good manufacturing practice standards, according to Panh. The company collects safety and sourcing information from suppliers and uses internal systems to document materials and production.

Panh said Utah’s requirements have already pushed Dragonfly toward the standards expected of conventional controlled-substance manufacturers.

He expressed concerns over the need for product consistency when cannabis is used by patients with cancer, autoimmune diseases and other serious conditions. Manufacturers must be able to document what is in a product, where its ingredients came from, and whether one batch is consistent with the next.

Finished-product testing provides only part of the record. A certificate of analysis can report cannabinoid potency and screen for designated contaminants, but it does not document every supplier, material or production step.

“How are you going to prove to anybody what is actually in your product?” Panh said. “How are you going to prove that your product was derived safely?”

Quality management systems used in pharmaceutical production track each stage of manufacturing. They also document deviations, investigations, and corrective actions when a batch does not meet specifications.

Panh expects medical buyers to look closely at testing, residual solvents, pesticides, ingredient sourcing and manufacturing records before purchasing cannabis products. A pharmacist or medical facility unfamiliar with cannabis is likely to favor suppliers whose standards resemble those already used for other medicines.

Dragonfly has invested heavily in these systems, he said. The added controls increase production costs and may prevent the company from offering the least expensive products in the market.

 

Dragonfly Is Preparing for Interstate Commerce

Utah’s limited-license system restricts how much Dragonfly can expand inside its home state, limiting its growth opportunities.

State law prevents a single operator from controlling more than 25 percent of Utah’s pharmacy licenses. Dragonfly currently has two locations, while Curaleaf holds four.

Utah plans to open a 16th medical cannabis pharmacy in Moab. A 17th license is expected to follow, although existing Utah operators will not be eligible to receive it, according to Panh.

“We don’t have an opportunity to grow if there is no opportunity to go interstate commerce,” he said.

Dragonfly is pursuing DEA registration partly to be ready if federally authorized interstate sales become possible.

Panh envisions a system in which a DEA-registered manufacturer supplies another registered medical facility. A conservative state without a cannabis program could provide patients with access without first licensing in-state cultivation and manufacturing.

Idaho is a like prospect since it shares a border with Utah but has not established a medical cannabis program. A future federal system could allow an Idaho pharmacy to obtain products manufactured by a registered Utah company, depending on the rules adopted by federal and state regulators.

Panh believes transactions between DEA-registered facilities could eventually offer the ability to do business across state lines.

“If you are a traditional pharmacy in another state and you want products that are GMP manufactured, that are registered with the DEA, who are you going to buy those from?” he said.

Schedule III does not currently establish unrestricted interstate commerce for products made under state cannabis programs. DEA registration, FDA requirements, and state licensing laws will determine which businesses may manufacture, transport, and dispense them.

Dragonfly does not intend to become the immediate test case through an unauthorized shipment, Panh said. Its registration and manufacturing investments are intended to put the company in a position to act once regulators establish a workable route.

 

We Still Need FDA Approval

The FDA has remained conspicuously absent while state cannabis markets developed without a federal framework for their products. Schedule III could finally bring the agency into a more active role.

Companies seeking approval for products intended to treat a specific condition must provide evidence of safety, efficacy, and manufacturing consistency. GMP compliance supports an application but does not replace clinical research.

Panh believes whole-plant products may have a future under the FDA’s botanical drug pathway, which accommodates complex plant-derived mixtures rather than a single isolated compound. Manufacturers must prove consistency across raw materials, production processes and finished products, a challenge when cannabis varies by cultivar, growing conditions, harvest and extraction method.

Panh pointed to German pharmaceutical company Vertanical and its whole-plant cannabis drug candidate for chronic lower back pain. Its progress could help establish how regulators evaluate medicines containing several cannabis compounds.

Few cannabis businesses have the capital to conduct late-stage clinical trials or complete a new drug application. Pharmaceutical companies have much larger research budgets and extensive experience with FDA approval.

 

Utah’s Need for Medical Cannabis

Dragonfly entered the Utah market partly in response to the state’s opioid epidemic and mental health needs. Panh said Utah’s conservative culture and religious attitudes toward alcohol and other substances have contributed to a greater reliance on medications prescribed by doctors.

Utah has consistently reported a higher rate of lifetime depression than the country overall, while its suicide death rate also exceeds the national rate.

Medical providers remain reluctant to recommend cannabis, however. Panh estimated that about 1,100 of Utah’s more than 30,000 providers participate in the program.

“I don’t fault them,” he said. “You want me to just start prescribing cannabis, and I don’t even know about it?”

Utah may also face a shortage of cannabis-trained pharmacists. Panh estimated that roughly 100 pharmacists have completed the education required to work in the state program. Demand for cannabinoid training could rise quickly if pharmacists become part of a national medical cannabis model.

 

Bringing Cannabis Into the Healthcare System

Utah still operates cannabis separately from conventional medicine.

Patients need a qualifying condition and state authorization, purchase products from cannabis-only pharmacies, and pay out of pocket.

Panh believes Schedule III could eventually move medical cannabis into the existing healthcare system. A doctor could prescribe it as a controlled substance, a pharmacy could dispense it and insurance could help cover the cost. Patients would no longer need to enter a separate state program.

Cost will be critical. Panh contrasted a $10 insurance copay for an opioid prescription with approximately $40 for an eighth of cannabis.

“It’s actually not a real choice that people have,” he said. “They’re going to take the opiates all day long because it’s all that they can afford.”

FDA approval, insurance reimbursement policies, and new federal regulations would be required before medical cannabis could operate this way. Utah’s use of pharmacists and medical providers offers an early version of the care model, even though it remains outside the conventional prescription and insurance system.

 

What Happens to the Dispensary?

Utah adopted a pharmacist-led system while much of the cannabis industry was moving toward adult use. Federal policy is now favoring a model centered on medical marijuana.

Dispensaries may have to look more like healthcare facilities as cannabis enters the medical system. Some states may require pharmacists in cannabis-only stores, as Utah does. Others may allow traditional pharmacies to dispense cannabis, following Georgia’s lead.

“Customers are transactional,” Panh said. “Patients, you’re building a relationship for a lifetime with them. Real patient care. It’s a very different model.”

A Survey of State CBD & Hemp Regulation Since The 2018 Farm Bill

By Brett Schuman, Jennifer Fisher, Brendan Radke, Gina Faldetta
1 Comment

Since the December 20, 2018 enactment of the Agricultural Improvement Act of 2018, better known as the Farm Bill, we have seen a number of new state laws addressing both the legality of hemp and products derived therefrom, most noticeably cannabidiol, better known as CBD. This piece provides a brief overview of some of the more interesting state laws concerning hemp and CBD, as well as recent developments.

Legality of Hemp

Since the passage of the Farm Bill, the vast majority of states have legalized the cultivation and sale of hemp and hemp products. However, certain states maintain laws barring some or even most forms of hemp.

The most stringent of those states is Idaho, where hemp remains illegal. In March 2020, Senate Bill 1345 – legislation that would have allowed for the production and processing of industrial hemp – died in the House State Affairs Committee, due to concerns that legalizing hemp would be the first step toward legalizing “marijuana”; that the bill contained too much regulation and that it was otherwise unworkable. As a result, Idaho is currently the only state without a legal hemp industry. Hemp with any THC, even at or below the 0.3 percent threshold under the Farm Bill, is considered equivalent to “marijuana” in Idaho and is illegal (see below for a discussion of CBD in Idaho).

Indiana, Iowa, Louisiana, and Texas have enacted bans on smokable hemp. Indiana law prohibits hemp products “in a form that allows THC to be introduced into the human body by inhalation of smoke.” Iowa has amended its Hemp Act to ban products introduced to the body “by any method of inhalation.” Louisiana prohibits “any part of hemp for inhalation” except hemp rolling papers, and Texas law prohibits “consumable hemp products for smoking.”

Some of these bans have been challenged in court. In Indiana, a group of hemp sellers requested an injunction against the smokable hemp ban in federal court, on the grounds that the federal Farm Bill likely preempted the Indiana law. In September of 2019, the district court issued the requested injunction, but the U.S. Court of Appeals for the Seventh Circuit overturned that decision in July 2020, stating that the order “swept too broadly.” The Seventh Circuit noted that the 2018 Farm Bill “expressly provides that the states retain the authority to regulate the production of hemp” and remanded the case for further proceedings.

Similarly, in Texas, hemp producers have sued in state court over the smokable hemp ban, questioning its constitutionality and arguing that it would result in a loss of jobs and tax revenue for the state. According to those producers, smokable hemp comprises up to 50 percent of revenue from hemp products. On September 17, 2020, Travis County Judge Lora Livingston issued a temporary injunction blocking enforcement of the law until trial, which currently is set to commence on February 1, 2021. Judge Livingston had previously issued a temporary restraining order to that same effect.

State Laws Regulating CBD

State laws and regulation on hemp-derived CBD are varied, and the legality of a CBD product often comes down to its form and marketing.

FDAlogoAs an initial matter, it must be noted that notwithstanding the Farm Bill the FDA currently prohibits hemp-derived CBD from being be sold as dietary supplements, and food (including animal food or feed) to which CBD has been added cannot be introduced into interstate commerce. As discussed below, a substantial minority of states, including California, follow the FDA’s current position on the permissibility of putting hemp-derived CBD in food or dietary supplements.

Certain states include strict limitations on CBD, none more so than (once again) Idaho. Lacking any legal hemp industry, Idaho restricts CBD products to those having no THC whatsoever, rejecting the generally accepted threshold of not more than 0.3 percent THC. Idaho law also requires that hemp CBD be derived only from “(a) mature stalks of the plant, (b) fiber produced from the stalks, (c) oil or cake made from the seeds or the achene of such plant, (d) any other compound, manufacture, salt, derivative, mixture, or preparation of the mature stalks, or (e) the sterilized seed of such plant which is incapable of germination.”

Kansas similarly prohibits CBD with any amount of THC, though the law is murkier than Idaho’s. While Senate Bill 282 allowed possession and retail sale of CBD effective May 24, 2018 by removing CBD oil from the definition of “marijuana,” this was broadly interpreted to apply to THC-free CBD only. Later legislation, Senate Substitute for HC 2167, effective July 2019, allowed the farming of hemp with THC levels aligned with the Farm Bill definition (i.e., 0.3 percent THC or lower), but expressly prohibited the use of industrial hemp in: cigars, cigarettes, chew, dip, or other smokeless forms of consumption; teas; liquids for use in vaporizing devices; or “[a] ny other hemp product intended for human or animal consumption containing any ingredient derived from industrial hemp that is prohibited pursuant to the Kansas Food, Drug and Cosmetic Act or the Kansas Commercial Feeding Stuffs Act,” though this final section provides that “[t] his does not otherwise prohibit the use of any such ingredient, including cannabidiol oil, in hemp products,” the law’s only reference to CBD. The Kansas Bureau of Investigation has reportedly made statements indicating that CBD with any level of THC remains illegal.

Just some of the many hemp-derived CBD products on the market today.

Mississippi only recently legalized the cultivation of hemp via Senate Bill 2725, the Mississippi Help Cultivation Act, which was signed into law on June 29, 2020. House Bill 1547, passed on April 16, 2019, imposed content requirements upon CBD products within Mississippi: to be legal in Mississippi, a CBD product must contain “a minimum ratio of twenty-to-one cannabidiol to tetrahydrocannabinol (20:1 cannabidiol:tetrahydrocannabinol), and diluted so as to contain at least fifty (50) milligrams of cannabidiol per milliliter, with not more than two and one-half (2.5) milligrams of tetrahydrocannabinol per milliliter.” Moreover, CBD products produced in Mississippi must be tested at the University of Mississippi’s lab. However, subject to these restrictions, Mississippi allows the sale of CBD products, including edibles, contrary to the restrictions of many of states considered friendlier to hemp.

Perhaps more surprising is Hawaii, which restricts the sale and distribution of CBD, aligning with the FDA’s guidance. In Hawaii it is illegal to add CBD to food, beverages, as well as to sell it as a dietary supplement or market it by asserting health claims. It is also illegal to add CBD to cosmetics, an uncommon restriction across the many states with CBD-specific laws and regulations. Unlike Idaho and Mississippi, which have no medical marijuana programs, Hawaii has long legalized marijuana for medical purposes and in January 2020 decriminalized recreational possession. Hawaii very recently enacted legislation allowing the production and sale of cannabis-infused consumable and topical products by medical cannabis licensees effective January 1, 2021, but this legislation did not address CBD. Given the foregoing, Hawaii’s restrictions on CBD stand out.

The structure of cannabidiol (CBD), one of 400 active compounds found in cannabis.

Beyond broad CBD restrictions, many more states prohibit the use of CBD within food, beverages, or as dietary supplements. For instance, twenty states – including California, Georgia, Illinois, Massachusetts, Michigan, New Jersey, New York, and Washington – prohibit the sale of CBD in food or beverage. In California, a bill to overhaul California’s hemp laws, Assembly Bill 2028, failed when the legislative session concluded on August 31, 2020 without a vote. AB 2028 would have allowed CBD in food, beverages, and dietary supplements (though, interestingly, it would have banned smokable hemp). As a result, California remains a relatively restrictive state when it comes to hemp-derived CBD, notwithstanding the legality of recreational marijuana.

New York allows the manufacture and sale of CBD, but requires CBD products to be labeled as “dietary supplements.” This mandate conflicts directly with the FDA’s position that CBD products are excluded from the definition of a dietary supplement. Further, despite the state’s categorization of CBD products as dietary supplements, New York prohibits the addition of CBD to food and beverages. These regulations have resulted in a confusing landscape for retailers and manufacturers in the Empire State.

Several states also have labeling requirements specific to CBD products. Batch numbers and ingredients are ubiquitous, but an increasingly common requirement is the inclusion of a scannable code that links to specific information about the product. States imposing this requirement include Florida, Indiana, Texas, and Utah. Indiana is viewed as having one of the more comprehensive labeling requirements for CBD products – or, depending upon your perspective, the most onerous.

Midterm Elections Bring Green Wave of Legalization

By Aaron G. Biros
No Comments

On Election Night in America, pundits on the news media were reporting on the blue wave of Democrats taking back control of the House of Representatives, a less-discussed green wave made its way through the ballots in a number of states. While not as big of a tidal force as we saw back in 2016, this election still brought a handful of states on the cannabis legalization train.

Measure 3 in North Dakota failed to get enough votes, but many seem to think this was somewhat expected, as the state is still working on implementing their medical framework years later and that this new measure was less than perfect.

However, here comes the good news: Missouri voters passed Amendment 2, which legalizes, regulates and taxes medical cannabis. Very interestingly, this measure includes language allowing for caregivers to grow up to six plants. Check out Tom Angell’s article on Forbes to learn more.

In Utah, Proposition 2 passed by a narrower margin than other states, but legislators in the state are already full steam ahead on legalizing medical cannabis. They planned to pass a bill with the same language in Prop 2 if it didn’t get enough votes. Regardless, Utah will begin working on implementing a regulatory framework for legal medical cannabis, per the voters’ request.

While the 2016 election saw a handful of states legalize recreational cannabis, only one state did so this time around: Michigan. Voters in Michigan passed Proposal 1, making it the ninth state in the country to legalize and regulate recreational cannabis. According to Matthew Schweich, deputy director of the Marijuana Policy Project, Michigan’s legalization is a major milestone for the country. “The passage of Proposal 1 is a major milestone for marijuana policy reform in the U.S. Michigan will be the first state in the Midwest to end marijuana prohibition and replace it with a system in which marijuana is regulated for adult use,” says Schweich. “Michigan is going to demonstrate that regulating marijuana works, and it will set a strong example for other states in the region and around the country.”